Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy

Acta Haematologica

Volumn 100, Issue 1, 1998, Pages 26-31

  Saleh, A W ^a   Duits, A J ^a,b   Gerbers, A ^a   De Vries, C ^a   Hillen, H F P ^c  

^a St Elisabeth Hospital Willemstad   (Netherlands Antilles)

^b Red Cross Bloodbank Curacao   (Netherlands Antilles)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Hemoglobin F; Hydroxyurea; Sickle cell anemia; Soluble adhesion molecules

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 3; INTERLEUKIN 6; PADGEM PROTEIN; STEM CELL FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STEADY STATE; VASCULAR ENDOTHELIUM;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CELL ADHESION MOLECULES; CYTOKINES; FEMALE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED;

EID: 0031877983     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040859     Document Type: Article

References (32)

1. Adekile Ad, Huisman THJ: Hb F in sickle cell anemia. Experientia 1993;49:16-27.
2. Platt OS, Thorington BD, Brambilla DJ: Pain in sickle cell disease: Rates and risk factors. N Engl J Med 1991;325:11-16.
3. Charache S, Dover G, Moyer M, Moore J: Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987;69:109-116.
4. Sumoza A, Bissotti RS: Treatment of sickle cell anemia with hydroxyurea: Results in twenty-six patients. Blood 1986;68:67a.
5. Platt O, Orkin S, Dover G, Beardsley P, Miller B: Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1987;74:652-656.
6. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW: Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990;322: 1037-1045.
7. Charache S, Terrin ML, Moore RD, Dover GJ, Barton DB, Eckert SV, McMahon RP, Bonds DR, Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia: Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332: 1317-1322.
8. Vichinsky EP, Lubin BH: A cautionary note regarding hydroxyurea in sickle cell diseases. Blood 1994;83:366-372.
9. Saleh AW, Velvis HJR, Gu, L-H, Hillen HFP, Huisman THJ: Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles. Acta Haematol 1997;98:125-129.
10. Ballas SK, Dover GJ, Charache S: Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989;32:104-111.
11. Adragna NC, Fonseca P, Lauf PK: Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994;82:553-560.
12. Pieters RC, Rojer RA, Saleh AW, Saleh AEC, Duits AJ: Molgramostim to treat SS sickle cell leg ulcers. Lancet 1995;345:528.
13. Saleh AW, Pieters RC, Duits AJ: rhGm-CSF (Molgramostim): A potent inducer of sickle cell vaso-occlusive crisis (abstract). 20th Annual Meeting National Sickle Cell-Disease Program, Philadelphia, 1995.
14. Francis RB, Haywood LJ: Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 1992; 84:611-615.
15. Francis RB Jr: Elevated fibrin D-dimer fragment in sickle cell anemia: Evidence for the activation of coagulation during steady state as well as in painful crisis. Haemostasis 1989;19: 105-111.
16. Swerlick RA, Eckman JR, Kumar A, Jeitler M, Wick TM: a4b1-integrin expression on sickle reticulocytes: Vascular cell adhesion molecule-1 dependent binding to endothelium. Blood 1993;82:1891-1899.
17. Duits AJ, Pieters RC, Saleh AW, van Rosmalen E, Rojer RA: Soluble VCAM-1 levels in symptomatic and non-symptomatic sickle cell patients. Clin Immunol Immunopathol 1996; 81:96-98.
18. Solovey A, Lin Yi, Browne P, Choong S, Wayner E, Hebbel R: Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997;337:1584-1590.
19. Croizat H: Circulating cytokines in sickle cell patients during steady state. Br J Haematol 1994;87:592-597.
20. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP: Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl J Med 1994;330: 1639-1644.
21. Umemura T, al-Khatti A, Donahue RE, Papayannopoulou T, Stamatoyannopoulos G: Effects of interleukin-3 and erythropoietin on in vivo erythropoiesis and F-cell formation in primates. Blood 1989;74:1571-1576.
22. Migliaccio AR, Migliaccio G, Brice M, Constantoulakis P, Stamatoyannopoulos G, Papayannopoulou T: Influence of recombinant hematopoietins and of fetal bovine serum on the globin synthetic pattern of human BFU-E. Blood 1990;76:1150-1157.
23. Miller BA, Perrine SP, Bernstein A, Lyman SD, Williams DE, Bell LL, Olivieri NF: Influence of steel factor on hemoglobin synthesis in sickle cell disease. Blood 1992;79:1861-1868.
24. Bissé E, Wieland H: High performance liquid chromatographic separation of human haemoglobins: Simultaneous quantitation of foetal and glycated haemoglobins. J Chromatogr 1988;434:95-110.
25. Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV: Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993;82:3548-3555.
26. Bochner Bs, Klunk DA, Sterbinski SA, Coffman RI, Schleimer RP: IL-13 selectively induces vascular adhesion molecule-1 expression in human endothelial cells. J Immunol 1995; 154:799-803.
27. Smolinski PA, Offerman MK, Eckman JR, Wick TM: Double-stranded RNA induces sickle cell adherence to endothelium: A potential role for viral infection in vaso-occlusive pain episodes in sickle cell anemia. Blood 1995;85: 2945-2950.
28. Benjamin LJ, Yatco E, Swinson G: Interleukin-6, interleukin-1 and interleukin-1 receptor antagonist (IL-IRA), mediators and regulators of the inflammatory response are altered during acute painful vaso-occlusive crisis (abstract). National Sickle Cell Disease Program and American Pain Symposium, Philadelphia, 1993.
29. Chen CC, Rosenbloom CL, Anderson DC, Manning AM: Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IkB-a phosphorylation. J Immunol 1995;155:3538-3545.
30. Gibson FM, Scopes J, Daly S, Ball S, Gordonsmith EC: Haematopoietic growth factor production by normal and aplastic anaemia stroma in long-term bone marrow culture. Br J Haematol 1995;91:551-561.
31. Sherwood J, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL: Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 1986;67:44-49.
32. Croizat H, Nagel RL: Circulating BFU-E in sickle cell anemia: Relationship to percent fetal hemoglobin and BPA-like activity. Exp Hematol 1988;16:946-949.